(Q40430974)

20 September 2017

1 reference

title

Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection (English)

1 reference

20 September 2017

Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection (English)

1 reference

10.2165/00003088-199529010-00006

Crossref

DOI

https://api.crossref.org/works/10.2165/00003088-199529010-00006

26 May 2024

main subject

anti-retroviral agent

0 references

1 reference

B. N. Stretcher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7586898

26 May 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7586898

26 May 2024

publication date

1 July 1995

1 reference

Clinical Pharmacokinetics

20 September 2017

published in

1 reference

20 September 2017

volume

29

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

46-65

1 reference

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation

20 September 2017

cites work

1 reference

12 December 2020

Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis

1 reference

12 December 2020

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

1 reference

12 December 2020

Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis

1 reference

12 December 2020

Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia

1 reference

12 December 2020

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

1 reference

12 December 2020

Pharmacokinetics of zidovudine in patients with liver cirrhosis

1 reference

12 December 2020

Plasma viraemia as a marker of viral replication in HIV-infected individuals

1 reference

12 December 2020

Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring

1 reference

12 December 2020

Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction

1 reference

12 December 2020

Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate

1 reference

12 December 2020

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species

1 reference

12 December 2020

Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus

1 reference

12 December 2020

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

1 reference

12 December 2020

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi

1 reference

12 December 2020

Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells

1 reference

12 December 2020

Quantification of dideoxycytidine in human plasma by gas chromatography/mass spectrometry

1 reference

12 December 2020

Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports

1 reference

12 December 2020

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

12 December 2020

Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine

1 reference

12 December 2020

Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance

1 reference

12 December 2020

Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro

1 reference

12 December 2020

Pharmacokinetic disposition of zidovudine during pregnancy

1 reference

12 December 2020

Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection

1 reference

12 December 2020

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro

1 reference

12 December 2020

Clinical pharmacokinetics of zidovudine. An overview of current data

1 reference

12 December 2020

Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

1 reference

12 December 2020

Analysis of Potential Risk Factors Associated with the Development of Pancreatitis in Phase I Patients with AIDS or AIDS-Related Complex Receiving Didanosine

1 reference

12 December 2020

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection

1 reference

12 December 2020

The association of clinical conditions and serologic tests with CD4 + lymphocyte counts in HIV-infected subjects without AIDS

1 reference

12 December 2020

Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure

1 reference

12 December 2020

Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum

1 reference

12 December 2020

The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals

1 reference

12 December 2020

Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients

1 reference

12 December 2020

Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection

1 reference

12 December 2020

Canadian multicenter azidothymidine trial: AZT pharmacokinetics

1 reference

12 December 2020

Therapeutic drug monitoring in cancer management.

1 reference

12 December 2020

Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex

1 reference

12 December 2020

Azidothymidine (zidovudine) transport by the human placenta

1 reference

12 December 2020

Zidovudine dosage. Nordic Medical Research Councils' HIV Therapy Group

1 reference

12 December 2020

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection

1 reference

12 December 2020

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

12 December 2020

Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis

1 reference

12 December 2020

Management of antiretroviral drug therapy in human immunodeficiency virus infection

1 reference

12 December 2020

Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.

1 reference

12 December 2020

Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS.

1 reference

12 December 2020

Preliminary analysis of the Concorde trial. Concorde Coordinating Committee

1 reference

12 December 2020

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

1 reference

12 December 2020

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy

1 reference

12 December 2020

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

12 December 2020

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

12 December 2020

Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides

1 reference

12 December 2020

Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease

1 reference

12 December 2020

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus

1 reference

12 December 2020

Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells

1 reference

12 December 2020

Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019.

1 reference

12 December 2020

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

12 December 2020

Hematologic Effects of AIDS Therapies

1 reference

12 December 2020

Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

1 reference

12 December 2020

Pharmacokinetic optimisation of anticancer therapy

1 reference

12 December 2020

Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers

1 reference

12 December 2020

In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes

1 reference

12 December 2020

Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate

1 reference

12 December 2020

Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection

1 reference

12 December 2020

Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection

1 reference

12 December 2020

Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells

1 reference

12 December 2020

3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA

1 reference

12 December 2020

High-performance liquid chromatographic determination of 2',3'-didehydro-3'-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine

1 reference

12 December 2020

Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex

1 reference

12 December 2020

Probenecid and zidovudine metabolism

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

Pharmacokinetics of zidovudine (azidothymidine). III. Effect of pregnancy

1 reference

12 December 2020

Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis

1 reference

12 December 2020

p24 antigenaemia, CD4 lymphocyte counts and the development of AIDS

1 reference

12 December 2020

CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine

1 reference

12 December 2020

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

12 December 2020

Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy

1 reference

12 December 2020

Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group.

1 reference

12 December 2020

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

1 reference

12 December 2020

Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine

1 reference

12 December 2020

Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection.

1 reference

12 December 2020

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee

1 reference

12 December 2020

Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations

1 reference

12 December 2020

Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.

1 reference

12 December 2020

Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction

1 reference

12 December 2020

Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1.

1 reference

12 December 2020

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

1 reference

12 December 2020

Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer

1 reference

12 December 2020

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

1 reference

12 December 2020

Evaluation of hiv p24 antigen, beta2-microglobulin, neopterin, soluble cd4, soluble cd8, and soluble interleukin-2 receptor levels in patients with aids or aids-related complex treated with 2′,3′-dideoxyinosine (ddl)

1 reference

12 December 2020

Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells

1 reference

12 December 2020

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

12 December 2020

Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro

1 reference

12 December 2020

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

1 reference

12 December 2020

Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes

1 reference

12 December 2020

A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories

1 reference

12 December 2020

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

1 reference

12 December 2020

Zidovudine with probenecid: a warning

1 reference

12 December 2020

3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion

1 reference

12 December 2020

Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV.

1 reference

12 December 2020

Thymidine and 3'-azido-3'-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways

1 reference

12 December 2020

Effects of 3'-azido-3'-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells

1 reference

12 December 2020

Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial

1 reference

12 December 2020

A method for the quantification of intracellular zidovudine nucleotides

1 reference

12 December 2020

Inhibition of mammalian DNA polymerase-associated 3' to 5' exonuclease activity by 5'-monophosphates of 3'-azido-3'-deoxythymidine and 3'-amino-3'-deoxythymidine

1 reference

12 December 2020

Pharmacologically directed ara-C therapy for refractory leukemia.

1 reference

12 December 2020

Zidovudine for the prevention of HIV transmission from mother to infant

1 reference

12 December 2020

Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity.

1 reference

12 December 2020

Zidovudine response relationships in early human immunodeficiency virus infection

1 reference

12 December 2020

1 reference

12 December 2020

Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells

1 reference

12 December 2020

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

1 reference

12 December 2020

A review of the pharmacokinetics of zidovudine in man.

1 reference

12 December 2020

Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate

1 reference

12 December 2020

The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group

1 reference

12 December 2020

Comparative pharmacokinetics of antiviral nucleoside analogues

1 reference

12 December 2020

Zidovudine: five years later

1 reference

12 December 2020

Drug interactions with zidovudine

1 reference

12 December 2020

Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity

1 reference

12 December 2020

Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.

1 reference

12 December 2020

Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-point

1 reference

12 December 2020

Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus

1 reference

12 December 2020

Drug-induced DNA hypermethylation and drug resistance in human tumors.

1 reference

12 December 2020

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

1 reference

12 December 2020

3'-Azido-3'-deoxythymidine potently inhibits protein glycosylation. A novel mechanism for AZT cytotoxicity

1 reference

12 December 2020

10.2165/00003088-199529010-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1008717727

0 references

1 reference